NLRP3 and colorectal carcinoma: Therefore, targeting NLRP3 and the NLRP3–MAPK–mTOR–S6K1 axis may be promising for the targeted therapy of CRC, particularly for patients with a resistance to mTORC1-targeted therapies [140].